Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 2, 2015, Pages 141-148

  Mackey, John R ^a   Ramos Vazquez, Manuel ^g   Lipatov, Oleg ⁱ   McCarthy, Nicole ⁿ   Krasnozhon, Dmitriy ^j   Semiglazov, Vladimir ^k   Manikhas, Alexey ^l   Gelmon, Karen A ^d   Konecny, Gottfried E ^o   Webster, Marc ^c   Hegg, Roberto ^p   Verma, Sunil ^e   Gorbunova, Vera ^m   Gerges, Dany Abi ^q   Thireau, Francois ^b   Fung, Helena ^b   Simms, Lorinda ^f   Buyse, Marc ^r   Ibrahim, Ayman ^s   Martin, Miguel ^h  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Translational Research In Oncology   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f Eli Lilly Canada   (Canada)

^g Centro Oncologico de Galicia   (Spain)

^h UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

ⁱ Acad of Sci of Bashkortostan Rep   (Russian Federation)

^j Leningrad Regional Oncology Dispensary   (Russian Federation)

^k N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^l City Clinical Oncology Dispensary   (Russian Federation)

^m N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁿ ICON Cancer Care   (Australia)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Hospital Pérola Byigton Centro de Referência da Saúde da Mulher   (Brazil)

^q Middle East Institute of Health   (Lebanon)

^r INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^s ImClone Systems   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TAXOID;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DECREASED APPETITE; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; INSOMNIA; LACRIMATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VENOUS THROMBOEMBOLISM; VERY ELDERLY; WEIGHT REDUCTION; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HAND-FOOT SYNDROME; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND-FOOT SYNDROME; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; STOMATITIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84920919864     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.1513     Document Type: Article

References (31)

1. Jitawatanarat P, Wee W: Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib. J Gastrointest Oncol 4:231-238, 2013
2. Ainsworth NL, Lee JS, Eisen T: Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 9:1793- 1805, 2009
3. Choueiri TK, Duh MS, Clement J, et al: Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 105:1247-1254, 2010
4. Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
5. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039-2045, 2012
6. O'Malley DM, Richardson DL, Rheaume PS, et al: Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 121:269-272, 2011
7. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
8. Eli Lilly: Lilly announces ramucirumab phase III lung cancer trial meets primary endpoint of overall survival: Ramucirumab improved survival in second-line study of patients with non-small cell lung cancer. https://investor.lilly.com/releasedetail.cfm?ReleaseID-826569
9. Lee CB, Socinski MA: Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: A review of recent clinical trials. Rev Recent Clin Trials 2:117-120, 2007
10. Mackey JR, Kerbel RS, Gelmon KA, et al: Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. Cancer Treat Rev 38:673-688, 2012
11. Belugali Nataraj N, Salimath BP: Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma. Cell Signal 25:277-294, 2013
12. Garon EB, Cao D, Alexandris E, et al: A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): Treatment rationale and study design. Clin Lung Cancer 13:505-509, 2012
13. Ghosh S, Sullivan CA, Zerkowski MP, et al: High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39:1835-1843, 2008
14. Meunier-Carpentier S, Dales JP, Djemli A, et al: Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 26:977-984, 2005
15. Krupitskaya Y, Wakelee HA: Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 10:597-605, 2009
16. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
17. Spratlin JL, Cohen RB, Eadens M, et al: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780-787, 2010
18. National Cancer Institute: Cancer Therapy Evaluation Program. http://ctep.cancer.gov
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
20. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer-Breast quality of life instrument. J Clin Oncol 15: 974-986, 1997
21. European Society for Medical Oncology: Ramucirumab in combination with paclitaxel improves overall survival in second line treatment for metastatic gastric cancer: The phase III RAINBOW study met primary endpoint. http://www.esmo.org/Oncology-News/Ramucirumab-in-Combination-With-Paclitaxel-Improves-Overall-Survival-in-Second-Line-Treatment-for-Metastatic-Gastric-Cancer
22. Wilke H, van Cutsem E, Cheul Oh S, et al: RAINBOW: A global, phase III, randomized, doubleblind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4TIE-JVBE). J Clin Oncol 32, 2014 (suppl; abstr LBA7)
23. Cameron D, Brown J, Dent R, et al: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial. Lancet Oncol 14:933-942, 2013
24. Slamon DJ, Swain SM, Buyse M, et al: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, nodepositive or high risk node-negative breast cancer. Presented at the 36th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013
25. Bear HD, Tang G, Rastogi P, et al: Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310-320, 2012
26. Gerber B, Loibl S, Eidtmann H, et al: Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers: Results from the Geparquinto study (GBG 44). Ann Oncol 24:2978-2984, 2013
27. von Minckwitz G, Eidtmann H, Rezai M, et al: Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366: 299-309, 2012
28. Andres AC, Djonov V: The mammary gland vasculature revisited. J Mammary Gland Biol Neoplasia 15:319-328, 2010
29. Lindholm EM, Krohn M, Iadevaia S, et al: Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 20:404-412, 2014
30. Chen X, Iliopoulos D, Zhang Q, et al: XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 508:103-107, 2014
31. Giuliano S, Pages G: Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95: 1110-1119, 2013